Entity
  • DimiCare Biotech

    Created in 2023
  • Social networks

    287
  • Activities

  • Technologies

  • Entity types

  • Location

    Internat de l'Archet, 151 Route de Saint-Antoine, 06200 Nice, France

    Nice

    France

  • Employees

    Scale: 2-10

  • Engaged catalyst

    12
    0 0
  • Added in Motherbase

    1 year, 3 months ago
Description
  • Value proposition

    goes FAR BEYOND
    (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases)

    Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed.
    Dimicare Biotech is building a great team involving Microbiology Medical doctors, Fundamental researchers, and Financial experts, assuring solid growth not only in the scientific but also in the business field.
    Currently, our projects have been awarded by the Innovation program from Labex SIGNALIFE (Young Entrepreneur Program) and we are currently searching for new funding to support the continuity of the project.

    If you are interested in our research and want to contact us for collaboration or just to talk, do not hesitate to contact me through any of the options available in my profile.

    Microbiology, Antimicrobial Resistance, Bacteria, Fungi, Parasites, Drug Development, and Medicinal Chemistry

  • Original language

    goes FAR BEYOND
    (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases)

    Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed.
    Dimicare Biotech is building a great team involving Microbiology Medical doctors, Fundamental researchers, and Financial experts, assuring solid growth not only in the scientific but also in the business field.
    Currently, our projects have been awarded by the Innovation program from Labex SIGNALIFE (Young Entrepreneur Program) and we are currently searching for new funding to support the continuity of the project.

    If you are interested in our research and want to contact us for collaboration or just to talk, do not hesitate to contact me through any of the options available in my profile.

  • Home

    Antibiotics, Resistance, Precision treatment, emergent pathogen, infectious disease, Drug Discovery, Biotech, HealthTech, Innovation, Research, Microbiology, Pharmacology, Infection,

  • https://www.dimicare-biotech.com/
Catalyst interactions
Catalyst TypeTweets Articles
INIZIÀ - Incubateur Territorial des Entreprises Innovantes de Corse INIZIÀ - Incubateur Territorial des Entreprises Innovantes de Corse
Business Consulting and Services
Other

19 Oct 2023


SATT Sud-Est
SATT Sud-Est
Research, National and local authorities, Research Services
SATT Sud-Est
Research, National and local authorities, Research Services
Other

14 Oct 2023


Social network dynamics
Similar entities
BETA
Loading...
Loading...